10:31 AM EST, 12/19/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Thursday it has filed a new drug application with the US Food and Drug Administration for vatiquinone to treat children and adults with Friedreich's ataxia, a rare neuromuscular disorder.

The application is supported by data from the placebo-controlled MOVE-FA study and two long-term studies that show a "significant" reduction in disease progression and demonstrate a "safe and well-tolerated" vatiquinone across all age groups, the company said.

Price: 45.60, Change: +0.14, Percent Change: +0.31